Piramal Pharma Ltd.

168.11-7.1 (-4.06%)

8 Jul, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Piramal Pharma Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	2,939	6,559	7,082	8,171	9,151	8,869
Cost of Operating Revenue	1,371	3,201	3,588	3,936	4,270	4,323
Gross Profit	1,567	3,358	3,494	4,235	4,881	4,546
Gross Margin	53.3	51.2	49.3	51.8	53.3	51.3
Total Operating Expenses	1,845	5,250	5,931	6,625	8,352	8,618
Operating Profit	1,094	1,309	1,151	1,547	799	251
Operating Margin	37.2	20.0	16.3	18.9	8.7	2.8
Financing Income/(Expense) - Net	141	-196	-341	-402	-371	-275
Profit before Taxes	687	485	-120	179	415	-176
Income Taxes	115	109	66	161	324	150
Profit after Tax	572	376	-186	18	91	-326
PAT Margin	19.4	5.7	-2.6	0.2	1.0	-3.7
EPS - Basic - ex Extraordinary Items	4.71	3.11	-1.53	0.14	0.69	-2.46
EPS - Diluted - ex Extraordinary Items	4.71	3.11	-1.53	0.14	0.68	-2.46
EBIT	1,094	1,309	1,151	1,547	799	251
EBITDA	1,238	1,895	1,828	2,287	1,571	1,075
EBITDA Margin	42.1	28.9	25.8	28.0	17.2	12.1

Balance Sheet

Abridged

Understanding Balance Sheet

Piramal Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR
Total Current Assets	1,768	4,067	4,835	5,464	5,797	7,192
Long-Term Investments	1,602	37	42	35	44	61
Property Plant & Equipment - Net	1,385	3,716	4,441	4,816	5,023	5,642
Total Non-Current Assets	3,989	8,730	9,687	9,847	9,881	10,773
Total Assets	5,757	12,797	14,523	15,312	15,678	17,965
Total Current Liabilities	1,472	3,033	3,843	4,369	3,766	4,758
Long Term Debt	7	2,708	3,485	2,602	3,313	4,435
Total Non-Current Liabilities	184	3,067	3,906	3,031	3,786	5,044
Total Liabilities	1,656	6,100	7,749	7,400	7,552	9,802
Total Shareholders' Equity	4,101	6,697	6,774	7,911	8,125	8,163
Total Equity	4,101	6,697	6,774	7,911	8,125	8,163
Total Liabilities & Equity	5,757	12,797	14,523	15,312	15,678	17,965

Cash Flow

Abridged

Understanding Cash Flow Statement

Piramal Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	308	996	576	791	979	863
Working Capital - Increase/(Decrease)	-228	-292	-295	-234	-488	527
Net CF from Operating Activities	80	704	281	557	491	1,390
Capital Expenditures - Net	55	857	945	710	659	877
Net CF from Investing Activities	-4,432	-1,894	-1,414	-456	-524	-869
Dividends Paid - Cash - Total	-	50	67	-	14	19
Stock - Issuance/(Retirement) - Net	3,523	-	-	1,050	-	3
Debt - LT & ST - Issuance/(Retirement) - Total	89	989	1,163	-989	21	283
Net Cash Flow from Financing Activities	4,498	939	1,096	47	7	267
Free Cash Flow to Equity	114	836	499	-1,142	-147	796
Free Operating CF net dividend	22	-235	-751	-155	-188	481
Free Operating CF	22	-185	-684	-155	-173	500

Business Segment Analysis

FY End:

Mar 26

Piramal Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 890.02 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 8,869.08 Cr

Assets

Pharmaceuticals (100.0%)₹ 17,965.04 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 250.69 Cr

Regional Segment Analysis

FY End:

Mar 26

Piramal Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (85.3%)₹ 7,567.22 CrWithin India (14.7%)₹ 1,301.86 Cr

Historical Segment Analysis

Track how Piramal Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceuticals	965	712	664	890

Frequently Asked Questions

What is the revenue of Piramal Pharma Ltd.?

The latest trailing twelve month revenue of Piramal Pharma Ltd. is ₹ 8,869.08 Cr, reflecting a 1-year growth of -3.08% and a 3-year CAGR of 7.79%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Piramal Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Piramal Pharma Ltd. is ₹ -325.94 Cr, with a 3-year earnings CAGR of -17.15%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Piramal Pharma Ltd.?

The trailing twelve month EBITDA of Piramal Pharma Ltd. is approximately ₹ 90.38 Cr (based on an operating margin of 1.02%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Piramal Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Piramal Pharma Ltd. is -2.46. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Piramal Pharma Ltd.?

The debt-to-equity ratio of Piramal Pharma Ltd. stands at 0.70. The interest coverage ratio is 0.27x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Piramal Pharma Ltd.?

The estimated book value per share of Piramal Pharma Ltd. is 61.52 (derived from a P/B ratio of 2.73 and market price of ₹ 168.11), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Piramal Pharma Ltd.?

The trailing twelve month operating cash flow of Piramal Pharma Ltd. is ₹ 1,389.71 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Piramal Pharma Ltd. report consolidated or standalone financials?

Piramal Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.